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Study Summary 
 
Title Towards understanding ethnic differences in the progression to 
type 2 diabetes: a preliminary phenotyping study in people 
with recent-onset diabetes in SE London 
 
Short Title SouL-DeEP: the South London Diabetes and Ethnicity 
Phenotyping Study 
Protocol 
Numbers 
Version #1 31/10/2012 
REC# 12/LO/1859 
Study Sponsor Sponsored by Kings College London (Dr Keith Brennan) 
Principal 
Investigator 
Dr Louise Goff 
Study Design Single time-point observational comparison study of two 
ethnic groups 
Study Duration 18 months 
Study Center(s) King’s College London, Franklin-Wilkins building, Stamford 
Street, London SE1 9NH 
Objectives The primary objective is to assess, in people of black West 
African and white European origin with type 2 diabetes, insulin 
secretory reserve by graded glucose infusion insulin action. 
Secondary objectives are to assess liver and peripheral tissue 
insulin sensitivity for glucose metabolism; insulin sensitivity of 
lipolysis; visceral, intramyocelluar, intrahepatocellular and 
intrapancreatic fat accumulation; metabolic flexibility during 
the euglycaemic clamp using indirect calorimetry; and post-
prandial insulin and incretin secretion during a meal tolerance 
test. 
Number of 
Subjects 
20 BWAO and 20 WEO (recruit n=23 per group, allowing for 
10% dropout) 
Main Inclusion 
/ Exclusion 
Criteria 
Participants must be males, 18-65 years of age, have a body 
mass index of 25-40 kg/m2 and be able to provide informed 
consent.  Type 2 diabetes must have been diagnosed 
(according to WHO criteria) within the previous 5 years, be 
treated with nothing more than lifestyle +/- metformin and 
have an HbA1c of 8.0% or less. 
 
Participants will be excluded if treated with thiazolidinediones, 
insulin, oral steroids or beta-blockers, or drugs/conditions 
considered by the investigators to have significant impact on 
the study protocol or outcomes; with a serum creatinine of 
>150 mmol/l; with a serum alanine transaminase level >2.5 
fold above the upper limit of the reference range; 
contraindications for magnetic resonance imaging; positive 
auto-antibodies for anti-insulin, anti-GAD or anti-A2; sickle cell 
disease (trait permitted); or unwillingness/unable to follow 
protocol.  
Statistical 
Methods 
Summary statistics will be presented as means, standard 
deviations and proportions. The t-test will be used to compare 
the 2 groups for the primary analysis. Further exploratory 
analyses using multiple regression will look at potential 
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confounding factors namely anthropometric, biomedical and 
clinical variables. Skewed data will be transformed and 
presented as unadjusted and adjusted means, confidence 
intervals, and regression coefficients. 
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List of Abbreviations 
BWAO  Black West African Origin 
CRF  Clinical Research facility 
GCP  Good Clinical Practice 
GGI  Graded glucose infusion 
ISR  Insulin secretory reserve 
MRI  Magnetic resonance imaging 
MRU  Metabolic research unit 
MTT  Meal tolerance test 
PIS  Participant information sheet 
REC  Research Ethics Committee 
SAE  Serious Adverse Event 
SouL-D  South London Diabetes study 
T2DM  Type 2 diabetes 
WEO   White European Origin 
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1. Study Contact Information 
1.1 Sponsor Contact Information 
Name:   Keith Brennan  
       Address:      Head of Administration (Health Schools) 
                           Room 1.8, Hodgkin Building, Guy’s Campus,  
                           King’s College London, London, SE1 4UL 
Tel:   0207 848 6960 
Fax:  020 848 6394 
Email:   keith.brennan@kcl.ac.uk 
       
1.2 Principal Investigator Contact Information 
Name:   Dr Louise Goff (Chief Investigator) 
   Lecturer in Nutritional Sciences 
Address:  Division of Diabetes & Nutritional Sciences, Franklin-Wilkins 
Building, Room 4.10, Stamford Street, London SE1 9NH 
Tel:   0207 848 4380 
Fax:  0207 848 4171 
Email:   louise.goff@kcl.ac.uk 
 
1.3 Sub-Investigator Contact Information 
Name:   Professor Stephanie Amiel (Senior Investigator) 
RD Lawrence Professor of Diabetic Medicine and Honorary 
Consultant Physician 
Address:  Diabetes Research Group, 3rd floor Weston Education Centre, 
Denmark Hill Campus, Cutcombe Road, London, SE5 9RJ 
Tel:   020 7848 5645 
Email:   Stephanie.amiel@kcl.ac.uk 
 
Name:   Professor Janet Peacock (Co-Investigator) 
   Professor of Medical Statistics 
Address:  Division of Health and Social Care Research, King’s College 
London, School of Medicine, 7th floor Capital House, 42 Weston 
Street, Guy’s Campus, London, SE1 3QD 
Tel:   020 7848 6651 
Email:   janet.peacock@kcl.ac.uk 
 
Name:   Professor Margot Umpleby (Co-Investigator) 
Head of Diabetes and Metabolic Medicine  
Address:  Postgraduate Medical School, Daphne Jackson Road, Manor 
Park, University of Surrey, Guildford, GU2 7WG 
Tel:   01483 688579 
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Email:   m.umpleby@surrey.ac.uk 
 
Name:   Dr Stephen Keevil (Collaborator) 
   Consultant Physicist and Reader in Medical Physics 
Address:  Division of Imaging Sciences and Biomedical Engineering, 
King’s College London, St Thomas’ Hospital, Westminster 
Bridge Road, London, SE1 7HY 
Tel:   020 7188 3054 
Email:  stephen.keevil@kcl.ac.uk  
 
 
Name:   Dr Geoff Charles-Edwards (Collaborator) 
   Prinicipal Clinical Scientist (GSTT) 
                    Honorary Lecturer(KCL) 
Address:  Division of Imaging Sciences and Biomedical Engineering, 
King’s College London, St Thomas’ Hospital, Westminster 
Bridge Road, London, SE1 7HY 
Tel:   020 7188 3054 
Email:  geoff.charles-edwards@kcl.ac.uk 
 
1.4 Key Study Personnel 
  
Name:  Dr Cynthia Mohandas 
  Clinical Research Fellow & Study Coordinator 
Address:  Diabetes Research Group,  
                    Division of Diabetes & Nutritional Sciences, 
                    Franklin-Wilkins Building, Room 4.19, Stamford Street, London 
SE1 9NH 
  Tel:   0207 848 4546 
  Fax:  0207 848 4171 
  Email:  cynthia.mohandas@kcl.ac.uk 
 
Name: Andrew Pernet  
Senior Research Nurse 
Address:  Diabetes Research Group, 3rd flr Weston Education Centre, 
Denmark Hill Campus, Cutcombe Road, London, SE5 9RJ 
Email:  andrew.pernet@kcl.ac.uk 
 
 
Name: Bula Wilson  
Research Nurse 
10 
 
SouL-DeEP Study   21/12/2012         Version 2.0    REC Reference: 12/LO/1859 
Address:  Diabetes Research Group, 3rd floor Weston Education Centre, 
Denmark Hill Campus, Cutcombe Road, London, SE5 9RJ 
Email:  bula.m.wilson@kcl.ac.uk 
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2. Scientific Background 
 
The prevalence of T2DM in UK black communities is 2-3 times higher than in the 
white European community, and the age of onset is younger (1).  There are 
phenotypic differences in the presentation of T2DM in black patients that have 
implications for clinical management but these are not fully understood.  People of 
BWAO are characteristically insulin resistant (2-4) and hypertensive (5), but with a 
cardioprotective lipid profile (low total and LDL-cholesterol, high HDL-cholesterol and 
low triglycerides in blood) (2, 6) which may relate to the lower rates of myocardial 
infarction (heart attack) seen in this group. Other key differences in the 
pathophysiology of T2DM in black people have been recognised including lower 
visceral fat accumulation or ‘central adiposity’ (6-9). Studies of other ectopic fat 
depots in BWAO people are limited but suggest intramyocellular and 
intrahepatocellular lipids are relatively low (10). There has been extensive 
investigation of pancreatic β-cell function in African-American (AA) populations, 
suggesting a higher compensatory insulin secretory response to early insulin 
resistance, predisposing to more rapid β-cell failure in this ethnic group (11-13).  We 
have recently demonstrated this hyperinsulinaemia in UK-dwelling African-Caribbean 
people, using the intravenous glucose tolerance test (14).  Studies of AA children 
and adolescents have suggested that hyperinsulinemia in this group is a function of 
reduced hepatic insulin extraction rather than increased pancreatic secretion, which 
would lead to peripheral hyperinsulinemia; such an hepatic effect would effectively 
conserve β-cell function (12).  These studies present persuasive initial evidence that 
the pathophysiological development of T2DM in BWAO populations is different from 
that of other groups but require further investigation in the UK BWAO population. In 
the UK, the BWAO population has preserved to date the cardioprotective lipid profile 
and lower cardiovascular disease rates even in T2DM patients described above, 
which has been lost in African American populations. The UK BWAO population is less 
genetically mixed and has shorter and less complete acculturation of diet and 
lifestyle. Furthermore, existing studies in African Americans have been small, used 
surrogate markers of important metabolic processes and different aspects of 
metabolism have been studied in different groups. Our hypothesis is that, compared 
to people of WEO, people of BWAO with early T2DM will have (1) markedly greater 
insulin deficiency associated with (2) exaggerated peripheral insulin resistance. 
Additionally (3) low visceral and hepatic fat accumulation will be associated with (4) 
relatively preserved hepatic insulin sensitivity in BWAO people. It should be noted 
that this study is a first phase of a wider investigation of metabolic responsiveness in 
BWAO and WEO people with lesser degrees of glucose intolerance than frank T2DM, 
which ultimately will allow us to describe the pathogenesis of progression to diabetes 
in the two populations. 
Hypothesis 
We hypothesise that, compared to people of WEO, people of BWAO with early T2DM 
will have (1) markedly greater insulin deficiency associated with (2) exaggerated 
peripheral insulin resistance. Additionally (3) low visceral and hepatic fat 
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accumulation will be associated with (4) relatively preserved hepatic insulin 
sensitivity in BWAO people. 
3. Study Objectives 
3.1 Primary Objective 
The primary objective is to assess insulin secretory reserve (ISR) by graded 
glucose infusion (GGI). 
3.2 Secondary Objectives 
Secondary objectives are to assess hepatic and peripheral insulin sensitivity 
for glucose metabolism; insulin sensitivity of lipolysis; visceral, 
intramyocellular, intrahepatocellular and intrapancreatic fat accumulation; 
metabolic flexibility; and post-prandial insulin and incretin secretion. 
4. Study Design 
4.1 Overview of Study Design 
This is single time-point observational comparison of β-cell insulin secretory 
function; whole body insulin sensitivity; hepatic and peripheral insulin 
sensitivity of glucose metabolism; insulin sensitivity of lipolysis and 
intrahepatocellular, intrapancreatic and intramyocellular lipid storage in males 
of black West African (n=20) and white European origin (n=20), aged 18-65 
years, with newly-diagnosed T2DM (within 5 years of diagnosis).     
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Figure 1: a schematic of trial design and subject flow  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Identification of newly- diagnosed type 2 diabetes (nT2DM) 
Eligibility: diagnosed within previous 5 years, 
HbA1C≤ 8.0%, 
Black West African (BWAO) or White European (WEO) ethnicity 
SouL-D participants & completers 
Send invitation letter (L1) or telephone 
invitation 
Community recruitment 
Posters & leaflets in community practices, 
advert in community literature 
Not eligible 
No further inclusion. 
Send L3 to volunteer and L5 to GP 
Potential participants contact 
researchers 
Send Participant Information Sheet (PIS) & 
invite to screening 
Informed consent 
Screening assessment of eligibility  
(Visit S) 
Eligible 
Send L2 to participant and L4 to GP. 
 
Participants: 
Black West African Origin (BWAO), n=20 
White European Origin (WEO), n=20 
Food diary (4-day) 
Completed and returned prior to 
assessment visits 
VISIT A 
Meal Tolerance Test (MTT) 
Anthropometry 
3-day activity assessment 
 
VISIT B 
Magnetic resonance imaging 
(MRI) and spectroscopy 
(MRS) 
VISIT C 
Hyperinsulinaemic-euglycaemic 
clamp including stable isotope 
infusions of glucose + glycerol 
VISIT D 
Graded glucose infusion 
(GGI) 
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4.2 Anticipated Duration of the Investigation 
The study is anticipated to last 14 months from the enrolment of the first participant 
to the completion of the final report to Diabetes UK.   
Planned recruitment rate 
Preliminary data from the SouL-D study indicates that 76% of participants meet our 
inclusion criteria; 40% of these are of black ethnicity and 50% are of white ethnicity.  
We expect to screen 4 participants per week and recruit 2 per week for 5-6 months. 
Timescale of project 
On the basis of being able to have participants undertake Assessments A, B and D in 
pairs and Assessment C being performed individually we will need 100 assessment 
days.  We intend to perform assessments on 3 days per week, totalling 34 weeks.  
Therefore the following represents the planned timescale of the project: 
 
July – October 2012 
Preparation of protocol 
 
November 2012 
Ethics & R&D application 
 
December 2012 
Ethics approval 
 
January – February 2013 
Subject identification 
Commence recruitment and screening 
 
March 2013 
Commence outcome assessments 
 
August 2013 
Complete recruitment 
 
October 2013 
Complete outcomes assessment 
 
November – January 2014 
Sample analysis 
 
January – March 2014 
Data analysis 
 
March 2014 
Final report 
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4.3 Outcome Measures 
4.3.1 Primary Outcome 
The primary outcome measure upon which the study is powered is insulin secretory 
reserve (ISR) assessed via the graded glucose infusion (GGI).  
4.3.2 Secondary Outcomes 
Our secondary outcome measures are: 
1. weight, height, BMI, waist circumference; 
2. β-cell insulin secretory function, using a meal tolerance test; 
3. whole body, hepatic and peripheral insulin sensitivity of glucose metabolism, 
using the 2-step euglycaemic-hyperinsulinaemic clamp with infusion of labelled 
di-deuterated glucose ; 
4. insulin sensitivity of lipolysis, using stable isotope methods;  
5. intrahepatocellular, intrapancreatic and intramyocellular lipid accumulation using 
magnetic resonance imaging and spectroscopy (MRI/MRS); 
6. total body, visceral and subcutaneous fat distribution using MRI. 
4.4 Study Population  
Our participants have T2DM.  The South London Diabetes Study (SouL-D) shows that 
in the SE London region 40% of people with newly diagnosed diabetes are of black 
African-Caribbean origin and 50% are of white European origin.  
4.4.1 Sample Size 
The aims of this study are to assess differences, between two ethnic groups, in the 
following biomarkers: 1.) insulin secretory reserve 2.) whole body insulin sensitivity 
3.) hepatic insulin sensitivity 4.) peripheral insulin sensitivity. Our primary outcome, 
upon which our study is powered, is insulin secretory reserve. As this study is novel 
there are no directly comparable data to use for sample size calculations however we 
have used the limited adult data from Zoratti et al. (African-Caribbeans 1.13 (SD 
0.6) vs white-Europeans 0.80 (SD 0.4) (2) to calculate our sample size which 
indicates we will have 90% power to detect a 40% difference (approx. 0.5 SD) with 
a sample size of 20 in each group.  Using the more conservative data from Stefan et 
al. (15) we will have 80% power.  We will recruit ~23 per group, to get 20 to 
completion, allowing for a 10% drop-out. We have additionally performed power 
calculations using lipolysis and insulin sensitivity data and are confident that this 
sample size will detect differences in these also (16-18).  
4.4.2 Subject Recruitment 
Participants will be identified principally through the South London Diabetes (SouL-D) 
Study database. Participants of SouL-D who have documented consent to be 
approached about new research in diabetes will be invited by letter (L1) or telephone 
to participate in the study.  Other people with recent onset diabetes may be recruited 
16 
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in community (consenting SouL-D practices) and hospital diabetes clinics by poster 
and leaflet and by open advertisement in relevant community literature; these forms 
of recruitment will require the potential participant to contact the study team.  
Interested parties will be sent an participant information sheet (PIS) providing details 
of the study and those who provide informed consent will be invited to a health 
screening assessment (visit S) which will assess eligibility. 
 
4.4.3 Subject Screening 
Potential participants will be invited to attend a screening assessment (visit S).  
Participants will be instructed to attend the research facility at either King’s College 
Hospital or King’s College London Waterloo Campus, depending on participant 
convenience, in a fasted state (10hr overnight fast).  The screening visit will start 
with taking informed consent from the participants, followed by:  
1. Screening questionnaire (S1) including medical and drug history, self-declared 
ethnicity of self, parents and grandparents, MRI contraindication checklist (e.g. 
claustrophobia, metal implants or prostheses). 
2. Anthropometric measures, including height and weight, waist circumference and 
seated blood pressure. 
3. Fasting blood test including full blood count, renal and liver function, HbA1c, lipid 
profile, sickle cell trait and auto-antibodies for anti-insulin, anti-GAD and anti-A2. 
The screening assessment will take 30 minutes and afterwards the participants will 
be provided with a light breakfast meal.   
Participant eligibility will be assessed against the inclusion/exclusion criteria and 
‘fitness’ to participate will be assessed and signed off by a clinician within the 
research team.   
Potential participants will be informed, by telephone or email, of their eligibility to 
participate within 3 weeks of their screening appointment and appointments for their 
metabolic assessment days will be made – a letter (L2) will be sent to confirm the 
appointments and to instruct the participant on pre-study requirements.  Non-eligible 
participants will be sent a copy of their screening results (L3) and their GP will be 
informed of their results.  Following screening, a GP letter L4 (eligible) and L5 (not 
eligible)) will be written informing the GP of the nature of the study and the 
participants screening results (anthropometrics, blood pressure and biochemistry), a 
copy of the PIS will be included in the letter. 
4.4.4 Inclusion Criteria 
Subjects will be eligible to participate in the study if all of the following conditions 
exist: 
1.  18-65 years of age 
2. BMI of 25-40 kg/m2  
17 
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3. Black West African (BWAO) or white European ethnicity (WEO) (self-declared) 
4. T2DM diagnosed (according to WHO criteria) within 5 years  
5. T2DM treated with nothing more than lifestyle +/- metformin*  
6. HbA1c of ≤8.0% 
7. Able to provide informed consent 
*Metformin will be stopped 7 days before any procedure. 
4.4.5 Exclusion Criteria 
Subjects will be excluded from participation in the study if any of the following 
conditions exist: 
1. Thiazolidinedione treatment 
2. Insulin treatment 
3. Oral steroids treatment 
4. Beta-blockers treatment 
5. Drugs or conditions thought by the investigators to have significant impact on 
the study protocol or outcomes. 
6. Serum creatinine of >150 mmol/l 
7. Serum alanine transaminase level >2.5-fold above the upper limit of the 
reference range 
8. Contraindications for MRI 
9. Positive auto-antibodies for anti-insulin, anti-GAD or anti-A2 
10. Sickle cell disease (trait permitted) 
11. Unwillingness/inability to follow the protocol 
4.4.6 Exit / Discontinuation Criteria 
Subjects will exit the study if any of the following conditions exist: 
1. Subject voluntarily withdraws from the study. 
2. Subject death. 
3. Subject acquires any of the listed exclusion criteria. 
4. Subject completes the protocol. 
5. Subject is non-compliant with the protocol (see Section 5.5 for definition of 
non-compliance) 
6. Subject’s well-being, in the opinion of the investigators, would be 
compromised by study continuation. 
7. Subject experiences an adverse event 
5. Study Procedures 
5.1 Informed Consent  
All participants for this study will be provided with a PIS and consent form describing 
this study and providing sufficient information for participants to make an informed 
decision about their participation in this study.  The PIS and consent form will be 
submitted with the protocol for review and approval by the Research Ethics 
Committee (REC) for the study.  The formal consent of a participant, using the REC-
approved consent form, will be obtained before that participant is submitted to any 
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study procedure.  The participant must sign this consent form, and the investigator-
designated research professional obtaining the consent. The participant will be 
required to sign two copies of the consent form, one to be given to the participant 
and the other copy will be with the investigator for records. A blank copy of the REC-
approved form will be kept on-site and by the sponsor-investigator.   
 
Consent will be taken by Dr Cynthia Mohandas, Dr Louise Goff, Mr Andrew Pernet or 
Professor Stephanie Amiel who have undergone GCP and consent training and are 
experienced in patient communication and consent taking. All potential participants 
will have been given a PIS and will have had adequate time to read it, understand 
the protocol, the risks and burdens and benefits, and will have had time to ask 
questions.  The researchers will reiterate this information in person prior to taking 
consent.  Only participants who have capacity to provide consent for themselves will 
be recruited. 
Potential participants will have at least 24 hours to consider participation. However, 
if the patient prefers to consent at the time of obtaining the information sheet and 
consent form, they will be able to provide consent at that time.  If this is the case, 
the researcher will contact the patient 24 hours later to confirm their decision to be 
involved. 
It is essential that participants fully understand the requirements of the study and 
therefore participants without a good understanding of verbal or written English will 
not be included in the study as there is not the provision for translation or 
interpreters. 
5.2 Study Procedures 
All potential participants will complete a screening assessment (visit S).  Consented 
participants will be allocated an anonymised study ID code which will be used on all 
study documents.  Eligible participants will go on to complete four assessment visits, 
detailed below.   
5.2.1 SCREENING (Visit S) 
Prior to the screening visit (S) the potential participant will have been provided with 
a copy of the PIS.  The investigator will begin the screening visit by explaining the 
requirements of the study and offering to answer any questions.  The participant will 
be asked to give formal written consent in the presence of the researcher.  The 
participant will be given a copy of the PIS and signed consent form for their records. 
A screening assessment will be performed to include: 
 Age 
 Self-declared ethnicity of self, parents and grandparents 
 Date of diabetes diagnosis 
 Relevant past medical history & comorbidities 
 Current medications 
 Contraindications for MRI (e.g. metal implants/prostheses, claustrophobia, 
pace maker) 
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 Body weight 
 Height 
 Waist circumference, as the mid-point between the lowest rib and the iliac 
crest. 
 Seated blood pressure assessed with an automated sphygmomanometer, 
using the average of 3 measurements. 
 Blood sample will be taken for assessment of electrolytes and creatinine 
(renal function), liver function tests, full blood count and sickle cell trait, full 
lipid profile, fasting glucose, HbA1c and auto-antibodies for anti-insulin, anti-
GAD and anti-A2. 
The screening assessment is expected to take 30 minutes.  The participant will be 
offered a light meal after the screening appointment to avoid ill effects of prolonged 
fasting. Following telephone confirmation of eligibility the participants will be sent 
their screening results in the post (L2), non-eligible participants will be sent a copy 
of their screening results (L3) and their GP will be informed of their results.  
Following screening, a GP letter (L4 (eligible) and L5 (not eligible)) will be written 
informing the GP of the nature of the study and the participants screening results 
(anthropometrics, blood pressure and biochemistry), a copy of the PIS will be 
included in the letter. The eligible participants will be instructed on keeping a 4-day 
food diary prior to their first assessment visit.  This diary will include at least 1 
weekend day. Participants will be instructed to return the diary by post before their 
first assessment visit. 
ASSESSMENT VISITS (A-D) 
Assessment visits will be scheduled in random order. 
Participants will be required to undertake the following instructions in preparation for 
ALL assessment visits: 
 Refrain from strenuous exercise and physical activity in the 48 hours 
preceding the visit. 
 Refrain from consuming alcohol in the 24 hours preceding the visit. 
 Consume a standardised diet the day prior to the assessment visits. The diet 
will be matched to the participant’s daily energy requirements and provide 
~50% of calories from carbohydrates (30-35% fat, 15-20% protein) which 
will be spread evenly throughout the day, ensuring that no more than 30% of 
the daily carbohydrate load is consumed in the evening meal.   
 Refrain from eating or drinking anything other than water after 10pm on the 
evening before the visit or on the morning of the visit. 
5.2.2 ASSESSMENT A – Meal Tolerance Test (MTT) (19) 
The meal tolerance test (MTT) will be performed in the Metabolic Research Unit 
(MRU), Franklin-Wilkins Building, King’s College London.  The meal tolerance test 
consists of the consumption of a specified volume, based on body weight, of Ensure 
Plus milkshake drink (Abbott Nutrition, UK) in a 5 minute period.   
The following protocol will be undertaken: 
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 Upon arrival at the Metabolic Research Unit participants will have the meal 
tolerance test procedure explained to them in brief. 
 Seated blood pressure will be assessed using an automated sphygmomanometer.  
A series of THREE measurements, each 2 minutes apart, will be recorded. 
 An antecubital fossa cannula will be inserted in to the non-dominant arm using 
intradermal lignocaine (1%) to anaesthetise the skin and standard aseptic 
techniques. Two fasting samples 10 minutes (-10, 0 minutes) apart will be drawn 
and cannula flushed with 0.9% NaCl solution. The participant will consume the 
standardised test drink (Ensure Plus).  The volume of drink will be calculated 
based on 6cals (4mls) per kg body weight. The drink will be consumed within a 5-
minute period and no other liquids or foods will be consumed for the duration of 
the MTT. 
 Blood samples will be taken at 10, 20, 30, 40, 50, 60, 75, 90, 120, 150, and 180 
minutes for assessment of glucose, C-peptide and insulin. GLP-1 and GIP will be 
assessed at -10, 0, 30, 60, and 120.  At time points -10, 0, 30, 60 and 120 the 
blood sample volume will be 10mls and at all other time points the volume will be 
7.5mls.The total volume of blood collected will be 110 ml. 
 Between 150 and 180 minutes, participants will be fitted with the Actiheart 
activity monitor, which will be worn for 3 days, and instructions for removal and 
return will be explained. 
 Two urine samples will be taken at the start (fasting) and end of the study period 
for urinary C-peptide (UCPCR) evaluation. 
 At the end of the meal tolerance test, the intravenous cannula will be removed 
and the participants will be provided with a light lunch meal.   
5.2.3 ASSESSMENT B – MRI scanning (20, 21) 
Participants will report to the Clinical Imaging Department at Guy’s Hospital, London 
Bridge between 7.30 and 8am on the day of their appointment. 
The following protocol will be undertaken: upon arrival participants will be asked to 
complete a standard MRI safety screening form and will be instructed to change in to 
a hospital gown in order to ensure they are free from metal objects on their clothing. 
Following screening, the participant will be positioned lying supine in the scanner 
with MRI coils positioned around the body. Ear defenders will be worn, through which 
music can be played during the scan. 
 
The following imaging sequence will be acquired: 
- A whole-body imaging scan to provide fat and water images. Some images may be 
acquired in conjunction with the patient holding their breath hold, as is routinely 
performed during clinical MRI scans of the abdomen. In these cases the subject will 
be given clear instructions by the radiographer at the beginning and end of the 
breath hold period. 
- Spectroscopy from the soleus muscle in the lower leg to provide a localised 
assessment of intracellular and extracellular muscle fat. 
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If we find unexpected abnormalities we will inform the participant and their GP about it.  If 
anything else needs to be done we will ensure that a referral to the correct clinic for further 
investigations or treatment is made. 
5.2.4 ASSESSMENT C – 2-Step Hyperinsulinaemic-Euglycaemic 
Clamp With Stable Isotope Infusions (22) 
The 2-step hyperinsulinaemic-euglycaemic clamp will involve a 120 minute infusion 
of insulin at a dose of 10mU/m2/min (LOW dose) followed by a 120 minutes infusion 
of insulin at a dose of 40mU/m2/min (HIGH dose), with an adjusted infusion of 20% 
glucose in order to maintain euglycaemia. Each insulin infusion will be primed to 
produce a “square wave” hyperinsulinaemia, in which the steady state plasma 
concentration is achieved rapidly. In order to measure endogenous glucose 
production, a primed-continuous infusion of [6,6 2H2] glucose will be started 2 hours 
before the first insulin infusion and run for 360 minutes. To measure lipolysis, a 
continuous infusion of [2H5] glycerol will be started at the same time and run for 240 
minutes.  Fuel oxidation prior to and during the glucose infusion will be assessed 
using the Delta Trac ventilated hood indirect calorimeter. 
 
 
The timeline for these infusions is shown in the schematic diagram below: 
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[2H5] glycerol     
[6,6 2H2] glucose 
 Glucose infusion to maintain euglycaemia 
   Insulin 
10mU/m2/min 
Insulin 
40mU/m2/min 
            
Blood sampling at 30 min intervals, increased to 10 min intervals (-30-0, 90-120, 
210-240 mins) 
Sampling for assessment of plasma glucose at 5 min intervals  
 
 
Preparation procedures 
 Procedures will be carried out in the morning at the Clinical Research Facility of 
either King’s College Hospital, St Thomas’ Hospital or Guy’s Hospital. The 
participant will be admitted to the CRF at 07.30 am, having fasted from 22:00 
hours the previous evening.   
 Upon arrival at the CRF the participant will be weighed, without shoes and with 
light clothing.  The body surface area of the participant will be calculated using 
the Gehan and George formula, and insulin infusion rates determined. 
 The participant will have a cannula inserted into an antecubital fossa vein for 
infusions and a second cannula inserted retrogradely into the dorsum of the hand 
for blood taking. Intradermal lignocaine (1%) will be used to anaesthetise the 
skin and strict aseptic technique used.  0.9% NaCl solution will be used for 
flushing and patency. 
 Baseline plasma glucose will be assessed using the YSI glucose analyser.  If 
baseline plasma glucose is above 5mmol/l, the participant will follow the protocol 
for priming regimen in hyperglycaemic patients. Plasma glucose will be measured 
before commencing the glucose infusion and the procedure will be initiated only if 
the plasma glucose is ≤5 mmol/l (± 10%). 
 The hand cannula, which is to be used for sampling, will be placed in the heated 
hand warming unit (~600C), to achieve arterialized venous blood. 
 The insulin infusion will be prepared by drawing up 40 mls 0.9% NaCl into a 50ml 
syringe, adding 2ml autologous blood, and the insulin dose and made up to 
55mls with 0.9% NaCl.  
 
Clamp procedures 
 The labelled glucose and glycerol infusions will be started at -120 minutes. 
 Baseline blood samples will be drawn at time points -30, -20, -10 and 0 minutes.  
-120 -60 0 60 120 180 240 
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 At 0 minutes a blood glucose reading will be taken using the YSI glucose analyser 
to confirm the blood glucose is ≤5 mmol/l ± 10%. 
 Then a primed-continuous infusion of insulin (LOW dose, 10 mU/m2/min) from 0 
to 120mins followed by re-primed HIGH dose (40 mU/m2/min) from 120 to 
240min.  
 Plasma glucose will be clamped at 5 mmol/l throughout by adjusting an infusion 
of 20% glucose, according to 5min readings of plasma glucose concentration 
using a glucose oxidase method (Yellow Springs Analyser).  
 Plasma glucose will be assessed at time points -120, 0 and every 5 minutes 
thereafter until 240 minutes. Blood samples will also be taken at 30 min interval, 
increased to 10min during steady state periods (-30 –0; 90-120 and 210- 
240min) for measurement of plasma glucose and glycerol concentrations and 
enrichments; NEFA, insulin, C-peptide and glucagon. 
 At 240 minutes, when all the measurements have been taken, the isotope and 
insulin infusions will be stopped. 
 A final plasma glucose reading, after the participant has consumed a light lunch, 
will be performed making a total of 51 blood glucose readings will be taken 
throughout the procedure. Sampling for isotope enrichments, NEFA, insulin, c-
peptide and glucagon will occur at -30, -20, -10, 0, 30, 60, 90, 100, 110, 120, 
150, 180, 210, 220, 230, 240 minutes: a total of 16 samples will be taken. The 
total volume of 205 ml of blood will be taken during the whole procedure.  
 During this period, blood pressure, heart rate will be assessed approximately 
every 30 minutes.  
Post-infusion procedures 
 The patient will be given a carbohydrate containing meal and blood glucose will 
be checked. All cannulae will be removed when the blood glucose is stable or 
increasing. Once the patient is feeling well they will be able to leave, but will be 
advised to avoid heavy exercise for 24 hours. 
 
Indirect calorimetry 
 At time point -60 - -30 minutes, an assessment of fuel oxidation will be 
performed.  The ventilated hood will be placed over the participant’s head and 
the participant instructed to remain rested and awake.  The duration of this 
assessment will include a settling period and 15 minutes of steady state 
recording. 
 At time point 60 – 90 minutes a repeat assessment of fuel oxidation will be 
performed. 
5.2.5 ASSESSMENT D – Graded Glucose Infusion (GGI) (23-25) 
Participants will receive graded intravenous infusions of glucose at progressively 
increasing rates (1, 2, 3, 4, 6, and 8 mg/kg/min), for 40 minutes per step. Glucose, 
insulin, and C-peptide concentrations will be measured at fasting and 10, 20, 30, and 
40mins into each glucose infusion, additionally insulin will be measured at 2,4, and 8 
minutes in the 1,3 and 8 mg/kg/min infusion phases only.  
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 Procedures will be carried out in the morning at the Clinical Research Facility of 
either King’s College Hospital, St Thomas’ Hospital or Guy’s Hospital. The 
participant will be admitted to the CRF at 8 am having fasted from 22:00 hours 
the previous evening.  Upon arrival the participant will be weighed, without shoes 
and with light clothing, to allow calculation of the glucose infusion volumes. 
 The participant will have a cannula inserted into an antecubital fossa vein for the 
administration of the glucose infusion and a second cannula inserted retrogradely 
into the dorsum of the hand for blood sampling. Intradermal lignocaine (1%) will 
be used to anaesthetise the skin and strict aseptic technique used.  0.9% NaCl 
solution will be used for flushing and patency. 
 The sampling hand will be placed in the heated hand warming unit, to achieve 
arterialized venous blood. 
 Plasma glucose will be measured before beginning the infusion, using the YSI 
analyser.  If above 5 mmol/l a bolus of rapid acting insulin (0.007U/kg) will be 
administered followed by a low-dose continuous infusion for 20 minutes. Plasma 
glucose will be measured again before commencing the glucose infusion and the 
procedure will only be initiated if the plasma glucose is ≤5 mmol/l (± 10%).   
 A baseline/fasting blood glucose sample will be taken at 0 minutes.  The glucose 
infusions will be in the form of 20% dextrose and started at time 0 minutes. 
 The infusion rates are 1, 2, 3, 4, 6, and 8 mg/kg/min and each infusion rate will 
run for 40 minutes.  At the end of each infusion period, the 40 minute sample will 
be drawn and the glucose infusion rate will be immediately increased to the next 
rate. 
 Blood sampling will occur at 10, 20, 30, and 40 minutes.  Additionally, at time 
points 2, 4 and 8 minutes, only in the 1,3 and 8 mg/kg/min steps, insulin 
concentrations will also be analysed. At all other time points glucose, insulin and 
c-peptide concentrations will be analysed. A total of 204.5mls will be taken. 
 At the end of the 240 minute infusion period the intravenous cannulae will be 
removed and the participants should be provided with a light lunch meal. 
 
 
                          
If plasma 
glucose 
>5mmol/l 
give insulin 
bolus 
(0.007U/kg) 
followed by 
20 min low-
dose insulin 
infusion. 
Allow 20 min 
rest before 
commencing 
infusions. 
Glucose 
infusion 
1mg/kg/min 
Glucose 
infusion 
2mg/kg/min 
Glucose 
infusion 
3mg/kg/min 
Glucose 
infusion 
4mg/kg/min 
Glucose 
infusion 
6mg/kg/min 
Glucose 
infusion 
8mg/kg/min 
Blood samples at 10, 20, 30, 40 minutes of each infusion period 
Blood samples for insulin taken at 2,4 and 8 minutes only at 1,3 and 
8mg/kg/min steps 
 
 
-40 80 120 160 200 240 0 40 
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5.3 Study Timetable  
There is no requirement to space the visits over a specified period.  The minimum 
period between assessment visits will be 1 week.  A reasonable spacing for the visits 
is one per month so it is expected that participants will take between 6 weeks and 4 
months to complete the study.  The maximum period that a participant will be able 
to take to complete the study is 12 months as beyond this period there is 
considerable chance of phenotypic changes; participants who have not completed 
within this period will be withdrawn from the study.   
5.3.1 Study flowchart 
 
 Screening 
visit 
Visit A –Meal 
Tolerance 
Test 
Visit B – 
MRI & MRS 
Visit C – 
Euglycaemic 
Hyperinsulinaemic 
clamp 
Visit C – 
Graded 
Glucose 
Infusion 
Participant information 
and consent 
X     
Screening assessment  
X     
MRI scan   X   
Meal tolerance test  X    
Anthropometry  X  X X 
Venepuncture or 
cannulation  
X X  X X 
Hyperinsulinemic clamp     X  
Stable isotope infusion    X  
Graded glucose infusion     X 
Indirect calorimetry    X  
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5.3.2 Study gantt chart 
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1 08/10/12        
2 15/10/12        
3 22/10/12        
4 29/10/12        
5 5/11/12        
6 12/11/12        
7 19/11/12        
8 26/11/12        
9 3/12/12        
10 10/12/12        
11 17/12/12        
12 24/12/12        
13 31/12/12        
14 7/1/13        
15 14/1/13        
16 21/1/13        
17 28/1/13        
18 4/2/13   2/1     
19 11/2/13   6/3     
20 18/2/13   10/5     
21 25/2/13   14/7 3    
22 4/3/13   18/9 6    
23 11/3/13   22/11 9    
24 18/3/13   26/13 12    
25 25/3/13   30/15 15    
26 1/4/13   34/17 18    
27 8/4/13   38/19 21    
28 15/4/13   42/21 24    
29 22/4/13   46/23 27    
30 29/4/13   50/26 30    
31 6/5/13   54/28 33    
32 13/5/13   58/30 36    
33 20/5/13   62/32 39    
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34 27/5/13   66/34 42    
35 3/6/13   70/36 45    
36 10/6/13   74/38 48    
37 17/6/13   78/40 51    
38 24/6/13   82/42 54    
39 1/7/13   86/44 57    
40 8/7/13   90/46 60    
41 15/7/13    63    
42 22/7/13    66    
43 29/7/13    69    
44 5/8/13    72    
45 12/8/13    75    
46 19/8/13    78    
47 26/8/13    81    
48 2/9/13    84    
49 9/9/13    87    
50 16/9/13    91    
51 23/9/13    94    
52 30/9/13    97    
53 7/10/13    100    
54 14/10/13        
55 21/10/13        
56 28/10/13        
57 4/11/13        
58 11/11/13        
59 18/11/13        
60 25/11/13        
61 2/12/13        
62 9/12/13        
63 16/12/13        
64 23/12/13        
65 30/12/13        
66 6/1/14        
67 13/1/14        
68 20/1/14        
69 27/1/14        
70 3/2/14        
71 10/2/14        
72 17/2/14        
73 24/2/14        
74 3/3/14        
75 10/3/14        
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76 17/3/14        
78 24/3/14        
*1-2 screening days per week, 2-4 participants screened per week 
#3 days per week for assessment visits, 3 assessment visits completed per week 
5.4 Laboratory Testing Procedures 
 
The following laboratories will undertake analysis of the samples: 
 
Analysis Laboratory 
Screening assessments  
Insulin 
c-peptide 
GLP-1 
GIP 
King’s College Hospital 
Clinical Biochemistry 
Denmark Hill, London, SE5 9RS 
 
Dr Roy Sherwood (Head of Clinical Biochemistry 
Department)  
roysherwood@nhs.net 
Tracy Dew 
tracydew@nhs.net 
0203 299 3726 
Glucose 
Lipids 
NEFA 
King’s College London 
Diabetes & Nutritional Sciences Division 
Franklin-Wilkins Building, Laboratory 4. 
 
Anne-Catherine Perz (technician) 
Isotope enrichments University of Surrey 
Diabetes & Metabolic Medicine 
Postgraduate Medical School 
Guildford 
Tel: 01483 688579 
Email: m.umpleby@surrey.ac.uk 
 
 
5.4.1 Specimen Preparation 
Labelling 
All participant documentation and specimens will be labelled with a unique study ID 
code which is a pseudo-anonymised code used on all study documents and samples, 
no identifiable information should be recorded on participant documents or samples.  
The ID code will take the following format: SDIIXXXS, which refers to: 
 
SD – SouL-DeEP study 
II – participant first and last initial 
XXX – study number e.g. 001 
S – screening visit (S), visit A (A), visit B (B), visit C (C), visit D (D) 
The labelling should also record information on the time point of collection and the 
analyte e.g. GLUC -30, INS 120 
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Sample collection and processing  
Samples will be collected at time points shown in the sampling schedules below: 
 
 
Meal tolerance test – sampling schedule 
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A1, A2  
Glucose  
(2ml fluroride oxalate) 
X X X X X X X X X X X X X 
A3, A4 
Insulin & c-peptide (5ml 
plain clotted) 
X X X X X X X X X X X X X 
A5 
GIP & GLP-1  
(2.5ml EDTA) 
X X   X   X   X   
A6 
Urine 
X            X 
 
 
Euglycaemic hyperinsulinaemic clamp – sampling schedule 
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Glucose YSI 
analyser (0.5ml) 
X    X X X X X X X X X X X X X X X X X X X X X X 
B1, B2 Glucose  
(2ml fluoride 
oxalate) 
 X X X X      X      X      X  X  
B3, B4 Insulin & c-
peptide  
(5ml plain clotted) 
 X X X X      X      X      X  X  
B5, B6 NEFA  X X X X      X      X      X  X  
B7 Glucagon  X X X X      X      X      X  X  
B8, B9 Isotope 
enrichment 
 X X X X      X      X      X  X  
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Glucose YSI 
analyser (0.5ml) 
X X X X X X X X X X X X X X X X X X X X X X X X X X X 
B1, B2 Glucose  
(2ml fluoride 
oxalate) 
X  X      X      X      X  X  X  X 
B3, B4 Insulin & 
c-peptide (5ml 
plain clotted) 
X  X      X      X      X  X  X  X 
B5, B6 NEFA X  X      X      X      X  X  X  X 
B7 Glucagon X  X      X      X      X  X  X  X 
B8, B9 Isotope 
enrichment 
X  X      X      X      X  X  X  X 
 Graded glucose infusion – sampling schedule 
 -1
0
 
0
 
2
 
4
 
8
 
1
0
 
2
0
 
3
0
 
4
0
 
C1, C2  
Glucose  
(2ml fluoride oxalate) 
X X    X X X X 
C3 
Insulin  
(2.5ml plain clotted) 
X X X* X* X* X X X X 
C4, C5 
c-peptide  
(2.5ml plain clotted) 
X X    X X X X 
*only during 1,3 and 8mg/kg/min steps 
 
The samples require the following preparation and processing: 
 
Processing screening samples 
Sample Analysis Preparation requirements 
4ml EDTA (purple top) 
 
FBC,HbA1c, sickle 
cell trait 
Send to laboratory without 
processing – whole blood analysis 
2ml Fluoride oxalate 
(grey top) 
Glucose 
 
Spin in centrifuge at 3000 rpm for 
20 minutes at 4oC where possible.  
Plasma aliquoted into 2 cryovials 
and labelled accordingly. 
8.5ml Serum (gold top) Full lipid profile, 
U&Es,LFTs, anti-
GAD, 
anti-insulin, anti-A2 
Stand at room temperature for 30 
minutes. Spin in centrifuge at 3000 
rpm for 20 minutes at 4oC where 
possible.  Serum aliquoted into 2 
cryovials and labelled accordingly. 
 
Processing visit A, B, C,D samples 
Analyte Sampling tube 
Preparation 
requirements 
Volume 
requirements 
Glucose Fluoride oxalate (grey top) 
Spun within 2 
hours  
plasma can be 
frozen at -20'C 
200uL plasma 
Insulin Plain clotted tube (gold top) 
Spun within 2 
hours  
plasma can be 
frozen at -20'C 
200uL plasma 
C peptide Plain clotted tube (gold top) 
Spun within 2 
hours  
200uL plasma 
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plasma can be 
frozen at -20'C 
NEFA EDTA (Lilac top) 
Spun within 2 
hours  
plasma frozen at -
80'C 
200uL plasma 
GIP EDTA (Lilac top) 
Spun within 2 
hours  
plasma can be 
frozen at -20'C 
200uL plasma 
GLP-1 
EDTA + DDPIV additive on ICE 
(Lilac top) 
Spun immediately 
at 4'C  
plasma frozen 
immediatey at -
40’C 
200uL plasma 
Glucagon EDTA PLASMA plus Trasylol 
Samples will be 
taken on ice or 
into chilled tubes. 
Spun at 4’C. 
Stored at -800C. 
200uL plasma 
Isotope 
enrichment 
D5 Glycerol       
D2 Glucose 
 
 
Lithium Heparin(green top) 
Fluoride oxalate(grey top) 
Mix the tubes 
gently, keep on 
ice. Spin at 4oC 
3000rpm 10 mins.  
Stored at -800C. 
2 separate 1 ml 
plasma 
500 ul plasma 
 
5.4.2 Specimen Handling and Storage 
The screening samples will be analysed at King’s College Hospital Clinical 
Biochemistry Department.  The whole blood sample (EDTA tube), and one aliquot of 
plasma and one aliquot of serum will be sent to the labs for analysis.  A second 
aliquot of plasma and of serum will be stored as a spare at -20oC in case of lost 
samples. 
 
The assessment visit samples will be spun immediately (within 2 hours) at 3000 rpm 
and at 4oC where possible.  Aliquoting will be performed according to the following 
plan for each visit: 
 
Visit A samples and aliquots 
Type Volume 
(ml) 
Measurement Set # Aliquot 
volume 
(mls) 
Aliquot 
cap 
colour 
Fluoride 
oxalate 
2.5 Glucose 
Spare plasma 
A1 
A2 
0.5 
2 x 0.5 
Yellow 
Yellow 
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Plain 
clotted 
6 Insulin/c-peptide 
Spare serum 
A3 
A4 
0.5 
2 x 0.5 
Red 
Red 
EDTA + 
DDPIV 
4 GLP-1/GIP* A5 0.5 Green 
Urine 10 Urinary C-peptide A6 2 x 5 Clear 
*samples to be centrifuged, aliquoted and frozen  immediately. 
 
Visit C samples and aliquots 
Type Volume 
(ml) 
Measurement Set 
# 
Aliquot 
volume 
(mls) 
Aliquot 
cap 
colour 
Fluoride 
oxalate 
2.5 Glucose 
Spare plasma 
B1 
B2 
0.5 
2 x 0.5 
Yellow 
Yellow 
Plain 
clotted 
6 Insulin/c-peptide 
Spare serum 
B3 
B4 
0.5 
2 x 0.5 
Red 
Red 
EDTA 3 NEFA 
Spare 
B5 
B6 
0.5 
2 x 0.5 
Blue 
Blue 
EDTA 
 
1 Glucagon B7 0.5 Clear 
Lithium 
heparin 
4 D5 Glycerol 
 
B8 
 
2x1 
 
Purple 
 
Fluoride 
oxalate 
1 D2 Glucose B9 0.5 Purple 
 
Visit D samples and aliquots 
Type Volume 
(ml) 
Measurement Set 
# 
Aliquot 
volume 
(mls) 
Aliquot 
cap 
colour 
Fluoride 
oxalate 
2.5 Glucose 
Spare plasma 
C1 
C2 
0.5 
2 x 0.5 
Yellow 
Yellow 
Plain 
clotted 
3 Insulin C3 0.5 Red 
Plain 
clotted 
6 c-peptide 
Spare serum 
C4 
C5 
0.5 
2 x 0.5 
Red 
Red 
 
Aliquots will be racked in 10x10 cryogenic storage boxes.  Each aliquot will be 
labelled with the participant study ID code, the time point of collection and the 
aliquot set number.  The storage boxes will be labelled with the set number to allow 
sets to be stored together.  The sample storage will be mapped on an excel 
spreadsheet and a printed copy of this box map should be inserted into completed 
boxes.  The storage boxes will be stored in -80oC freezers at Franklin-Wilkins 
building.  The ‘spare’ aliquots will be used if there are any losses during analysis or 
for future studies assessing adiponectin, leptin, resistin, TNF-α, vitamin D, bile acids, 
proteomics, lipidomics and total fatty acids. Samples of urine will be stored in the 
HTA licensed -80oC freezer in the Metabolic Research Unit on 4th floor of the Franklin-
Wilkins building (HTA license # 12523). 
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Long-term storage of spare aliquots will be in Franklin-Wilkins building, 4th floor 
laboratory.  The sample custodian is Dr Louise Goff, who will be responsible for the 
safe keeping, analysis and disposal of the samples. 
5.4.3 Specimen Shipment 
Screening Samples 
Blood samples collected from participants attending the screening assessment should 
be couriered to King’s College Hospital the same day for analysis.  All samples will 
have the appropriate accompanying documents.  Each sample will be labelled with 
the participant study ID code.  Tubes will carry the date and the trial code and the 
participant’s date of birth.  For each participant form S2 will be completed and sent 
with the samples.  Samples will be appropriately packaged and sent to Tracy Dew/Dr 
Roy Sherwood, Dept. Clinical Biochemistry, King’s College Hospital, Denmark Hill, 
London SE5 9RS.  Upon receipt of samples a copy of T1 will be faxed by King’s 
College Hospital to acknowledge receipt of samples.  Spare aliquots will be stored in 
a -20oC freezer in the Diabetes & Nutritional Sciences Division. 
 
Assessment visit samples 
The following sets of samples will be analysed at King’s College Hospital, Dept. 
Clinical Biochemistry: A3, A5, B3, B7, C3, C4.  These sets will be couriered to King’s 
College Hospital upon completion of the study.  The samples must remain frozen 
during transit therefore an igloo box and dry ice will be used for transfer.  Upon 
receipt of samples a copy of T1 will be faxed by the King’s College Hospital Dept. of 
Clinical Biochemistry to acknowledge receipt of samples. 
 
Blood samples collected during Visit B for analysis of isotope enrichment will be 
analysed at the University of Surrey.  Sets B8 and B9 will be couriered to the 
University of Surrey upon completion of the study.  The samples must remain frozen 
during transit therefore an igloo box and dry ice will be used for transfer.  Upon 
receipt of samples a copy of T1 will be faxed by the University of Surrey to 
acknowledge receipt of samples. 
5.4.4 Laboratory Testing:  Normal Values 
 
 
Analyte 
Normal Values / 
Reference Range 
Glucose 
(fasting-plasma) 
3-7 mmol/L 
Urea 3.3-6.7 mmol/L 
Creatinine 40-130 μmol/L 
Total protein 60-80 g/L 
Albumin 35-50 g/L 
Bilirubin 3-20 μmol/L 
Alkaline phosphatase 30-130 IU/L 
AST 10-50 IU/L 
Gamma GT 5-55 IU/L 
Total cholesterol <5.2mmol/L 
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Triglycerides < 2.0mmol/L 
HDL-cholesterol > 1.0mmol/L 
LDL-cholesterol 1-3 mmol/L 
Total:HDL ratio < 4 
WBC 4.0-11.0 109/l 
RBC 4.50-5.80 1012/l 
Haemoglobin 13-16.5g/dl 
HCT 0.40-0.54 l/l 
MCV 77-95 fl 
MCH 25-34 pg 
MCHC 32-37.0g/dl 
RDW 11.0-15.0% 
Platelets 150-450 109/l 
MPV 7.4-10.4fl 
Neutrophils 2.2-6.3 109/l 
Lymphocytes 1.3-4.0 109/l 
Monocytes 0.2-1.0 109/l 
Eosinophils 0.0-0.4 109/l 
Basophils 0.0-0.1 109/l 
 
5.5 Study Protocol Compliance  
The study protocol must be completed by each participant within 12 months of 
screening, if a participant fails to do so they will be withdrawn from the study and a 
replacement participant recruited and will undertake the entire protocol.  Data from 
withdrawn participants will be included in the analysis. 
5.6 Deviations from the Clinical Protocol 
5.6.1 Protocol Deviations 
When a deviation from the protocol is necessary for an individual subject, the 
investigator must complete a description of the deviation from the protocol and 
justification on the Protocol Deviation Form (PDF).   
 
If a participant finds one procedure within the protocol unacceptable they will be able 
to continue in the study and withdrawn only from that procedure, a PDF form will be 
completed. 
5.6.2 Protocol Amendments 
Should changes in the study plan or protocol become necessary in the course of the 
study, those specific changes will be discussed and agreed upon by the Sponsor, its 
acting representative if appropriate, Investigator, and appropriate ethical approval 
obtained before the changes are implemented.  All changes will be documented as 
protocol amendments.   
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5.7 Subject Withdrawal 
5.7.1 How to Withdraw Subjects 
Criteria for withdrawal of subjects from the study 
This study is completely voluntary at all times.  Participants are free to withdraw 
from the study at any time without giving a reason.  Withdrawal from the study will 
not affect future care at King’s College Hospital in any way. 
 
Subjects will be withdrawn from the study if they:  
 develop any of the exclusion criteria listed above 
 fail to complete the protocol within 12 months of screening 
 adverse event associated with the study protocol 
 subject consent withdrawal 
 
The reason for subject withdrawal will be documented (W1 form).   
 
Replacement of withdrawn subjects 
We will aim to complete the study with 20 participants in each group.  In order to 
achieve this, we may need to recruit up to a maximum of 25 per group. Once 23 
subjects have been recruited in a group we will recruit further subjects to that group 
only in event of subject withdrawal or incomplete data collection.  
 
5.7.2 Data Collection and Follow-up for Withdrawn Subjects  
Data collected up to the time of participant withdrawal will be analysed where 
possible (unless the participants withdraw their consent).   
5.8 Participant honorarium 
Subjects will receive a payment for participation in this study as follows: 
People who attend the screening appointment, regardless of eligibility, will be able to 
claim travel expenses up to £5.  There will be no other payment for the screening 
appointments. 
Participants who attend the assessment visits will be able to claim travel expenses, 
up to £5, for each visit (4 visits) and this will be reimbursed to all participants who 
do and do not complete the protocol.  An honorarium of £40 for visits A and B and 
£80 for visits C and D, totalling £240, will be paid to participants completing the 
protocol. 
King’s College London non-staff claim forms will be completed and the honorarium 
paid directly to the participant. 
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6. Data Collection and Analysis 
6.1 Subject Population for Analysis  
This is a single time point cross-sectional comparison of two populations: people of 
white European origin (WEO) and people of black West African origin (BWAO).  All 
analysis will be to compare primary and secondary outcomes between these two 
groups. 
6.2 Statistical Methods 
Summary statistics will be presented as means and standard deviations (skewed 
data will be transformed prior to analysis).  Transformed data will be presented as 
unadjusted and adjusted means, and confidence intervals. 
 
Data Collected Analysis to be Performed 
Demographics 
data 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Insulin secretory 
reserve (ISR) 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Whole-body insulin 
sensitivity (M) 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Hepatic insulin 
sensitivity 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Peripheral insulin 
sensitivity 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
1st phase insulin 
response 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Fasting beta-cell 
responsiveness 
(M0) 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Post-prandial beta-
cell responsiveness 
(M1) 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
GLP-1 iAUC Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
GIP iAUC Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Intramyocellular Descriptive statistics; comparison of means 
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lipid storage between independent groups;  p < 0.05 
Intrahepatocellular 
lipid storage 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Intrapancreatic 
lipid storage 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Visceral fat volume Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Waist 
circumference, 
BMI 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
Fasting lipids, 
blood pressure 
Descriptive statistics; comparison of means 
between independent groups;  p < 0.05 
 
Further exploratory analysis using multiple regression will look at potential 
confounding factors namely anthropometric, biomedical and clinical variables. 
 
7. Safety and Adverse Events 
7.1 Definitions 
Adverse Event (AE) 
An adverse event (AE) is any symptom, sign, illness or experience that develops or 
worsens in severity during the course of the study.  Intercurrent illnesses or injuries 
will be regarded as adverse events.  Abnormal results of laboratory or diagnostic 
procedures are considered to be adverse events if the abnormality: 
 Results in study withdrawal 
 Is associated with a serious adverse event 
 Is associated with clinical signs or symptoms 
 Leads to additional treatment or to further diagnostic tests 
 Is considered by the Investigator to be of clinical significance. 
 
Serious Adverse Event (SAE) 
A serious adverse event (SAE) is any adverse event that is: 
 Fatal 
 Life-threatening 
 Requires or prolongs a hospital stay 
 Results in persistent or significant disability or incapacity 
 A congenital anomaly or birth defect 
Important medical events are events that may not be immediately life-threatening, 
but are clearly of major clinical significance and may be SAEs.  They may jeopardize 
the subject, and may require intervention to prevent one or the other serious 
outcomes noted above.   
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Hospitalization  
Hospitalization shall include any initial admission (even if less than 24 hours) to a 
healthcare facility as a result of a precipitating clinical adverse effect; to include 
transfer within the hospital to an intensive care unit.  Hospitalization or prolongation 
of hospitalization in the absence of a precipitating, clinical adverse effect (e.g., for a 
preexisting condition not associated with a new adverse effect or with a worsening of 
the preexisting condition; admission for a protocol-specified procedure) is not, in 
itself, a serious adverse effect. 
 
Unanticipated Problems Involving Risk To Subjects or Others (UPIRTSO) 
An adverse event that in the opinion of the Principal Investigator is unexpected, 
related to the device, and serious. 
 
7.2 Safety Monitoring Plan 
Emergency Medical Safety Contact: 
 Dr Cynthia Mohandas  
     Telephone:07871 922423 
  
7.2.1 Anticipated Risks / Risk Mitigation 
 
Study Procedure Anticipated Risks Risk Mitigation 
Venepuncture & 
intravenous 
cannulation 
Discomfort, slight bruising, 
fainting 
Trained phlebotomists will 
perform all blood draws. 
Strict aseptic technique and 
use of local anaesthetic. 
Health screening Possibility of detecting 
undiagnosed dyslipidaemia, 
anaemia, abnormal renal or 
liver function 
Participant’s GP will be 
informed of results and early 
treatment can be initiated. 
MRI scanning Possibility of detecting 
abnormalities 
A trained radiographer will 
inspect scans and a referral 
for further investigation will 
be made if any abnormalities 
are detected. 
Fasting blood testing 
and procedures (e.g. 
clamp) 
Possibility of hypoglycaemia Regular monitoring of blood 
glucose concentrations and 
provision of a meal at the end 
of each fasting procedure 
before the participant departs 
Isotope tracers Possible fear of preparation 
standards 
Prepared in a manufacturing 
unit which is part of a 
specials manufacturing unit 
(MS11387). This means that 
the unit has been inspected 
by the Medicine and 
Healthcare Products 
Regulatory Agency (MHRA) 
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and has been found to 
comply with the requirements 
of Good Manufacturing 
Practice (GMP). Extensive 
experience in using these for 
clamp studies by the research 
group members. 
 
7.2.2 Medical Monitoring for Participant Safety 
The Principal Investigator will oversee the safety of the study, including careful 
assessment and appropriate reporting of adverse events.  Medical monitoring will 
include a regular assessment of the number and type of serious adverse events.   
 
7.3 Adverse Event Reporting  
All Adverse Events occurring during the study period must be recorded.  The clinical 
course of each event will be followed until resolution, stabilization, or until it has 
been determined that study treatment or participation is not the cause.   
 
The Sponsor-Investigator will promptly review documented adverse effects and 
abnormal test findings to determine  
1) if the abnormal test finding should be classified as an adverse effect;  
2) if there is a reasonable possibility that the adverse effect was caused by the study 
protocol/procedures  
3) if the adverse effect meets the criteria for a serious adverse effect. 
 
If the Sponsor-Investigator’s final determination of causality is “unknown and of 
questionable relationship to the study protocol”, the adverse effect will be classified 
as associated with study protocol for reporting purposes.  If the investigator-
sponsor’s final determination of causality is “unknown but not related to the study 
protocol”, this determination and the rationale for the determination will be 
documented in the respective subject’s case history. 
 
7.3.1 Adverse Events 
All observed or volunteered adverse effects and abnormal test findings will be 
recorded in the subjects’ case histories.  For all adverse effects, sufficient information 
will be pursued and/or obtained so as to permit  
1) an adequate determination of the outcome of the effect (i.e., whether the effect 
should be classified as a serious adverse effect) and;  
2) an assessment of the casual relationship between the adverse effect and the 
procedure   
 
Adverse effects or abnormal test findings felt to be associated with the 
investigational procedures will be followed until the effect (or its sequelae) or the 
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abnormal test finding resolves or stabilizes at a level acceptable to the Sponsor-
Investigator. 
 
Adverse Events that do not qualify as Serious Adverse Events, or as Unanticipated 
Adverse Device Effects will be reported to the Sponsor at designate interval 
determined by the Sponsor. 
 
Adverse Events that do not qualify as Serious Adverse Events, or as Unanticipated 
Adverse Device Effects will be reported to the Ethics Committee with the continuing 
review progress report.   
7.3.2 Serious Adverse Events 
Investigators must report serious adverse events to the Study Sponsor within 24 
hours of learning of the event.  A serious adverse event form must be completed by 
the Investigator and faxed to the Study Sponsor within 24 hours.  Study Sponsor 
contact information for Serious Adverse Event Notification: 
 Keith Brennan 
 0207 848 6960 (Telephone) 
 0207 848 6394 (Fax) 
 
At the time of the initial report, the following information should be provided: 
 Study Identifier  Reason the event is classified 
 Study Center  as serious   
 Subject Number  Investigator assessment of 
 Event Description  association between event 
 Date of Onset  and study device 
Current Status  
      
Serious Adverse Events that are at least possibly related must be reported to the 
Ethics Committee within 10 working days.   
 
7.3.3 UPIRTSO Events 
Investigators are required to submit a report of UPIRTSO events to the Ethics 
Committee within 10 working days of first learning of the event. 
 
8. Data Handling and Record Keeping  
 
8.1 Confidentiality 
Information about study subjects will be kept confidential.   
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8.2 Source Documents 
Source Data are the clinical findings and observations, laboratory and test data, and 
other information contained in Source Documents.  Source Documents are the 
original records (and certified copies of original records); including, but not limited 
to, hospital medical records, physician or office charts, physician or nursing notes, 
subject diaries or evaluation checklists, pharmacy dispensing records, recorded data 
from automated instruments, x-rays, etc.  When applicable, information recorded on 
the CRF shall match the Source Data recorded on the Source Documents.   
 
8.3 Case Report Forms 
The study case report form (CRF) is the primary data collection instrument for the 
study.  All data requested on the CRF must be recorded.  All missing data must be 
explained.  If a space on the CRF is left blank because the procedure was not done or 
the question was not asked, write “N/D”.  If the item is not applicable to the 
individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any 
entry error has been made, to correct such an error, draw a single straight line 
through the incorrect entry and enter the correct data above it.  All such changes 
must be initialled and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For 
clarification of illegible or uncertain entries, print the clarification above the item, 
then initial and date it. 
 
A Case Report Form will be completed for each subject enrolled into the clinical 
study.  The investigator-sponsor will review, approve and sign/date each completed 
CRF; the investigator-sponsor’s signature serving as attestation of the investigator-
sponsor’s responsibility for ensuring that all clinical and laboratory data entered on 
the CRF are complete, accurate and authentic.   
 
8.4 Clinical Reports  
An annual progress report will be submitted to Diabetes UK.  Investigators will 
submit a final report of the clinical study to the sponsor and Diabetes UK within 6 
weeks of termination or completion of the clinical study or the Investigator’s part of 
the clinical study.  The principal investigator is responsible for submitting these 
reports. 
 
9. Study Monitoring, Auditing, and Inspecting 
9.1 Auditing and Inspections 
The investigator will permit study-related monitoring, audits, and inspections by the 
Ethics Committee, the sponsor, government regulatory bodies, and University 
compliance and quality assurance groups of all study related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data etc.).  
The investigator will ensure the capability for inspections of applicable study-related 
facilities (e.g. pharmacy, diagnostic laboratory, etc.). 
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Participation as an investigator in this study implies acceptance of potential 
inspection by government regulatory authorities and applicable University 
compliance and quality assurance offices. 
 
10. Ethical Considerations  
This study is to be conducted according to the Declaration of Helsinki (1996) and the 
principles of Good Clinical Practice, applicable government regulations and 
Institutional research policies and procedures. 
 
This protocol and any amendments will be submitted to a Research Ethics Committee 
and the Research and Development committees of King’s College Hospital NHS 
Foundation Trust and St Thomas’ and Guy’s Hospital NHS Foundation Trust for 
formal approval of the study conduct.  The decision of the REC concerning the 
conduct of the study will be made in writing to the investigator and a copy of this 
decision will be provided to the sponsor before commencement of this study.   
 
11. Study Finances  
This study is financed through a project grant from Diabetes UK. 
 
12. Publication Plan  
The results of the study will be reported at conferences and in peer-reviewed 
journals.  Dr Louise Goff and Professor Stephanie Amiel have the primary 
responsibility for publication of any results of the study and are required to provide 
approval before any information can be used or passed on to a third party. 
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